The European Medicines Agency's committee on Friday recommended extending the use of Eli Lilly's blockbuster drug Mounjaro ...
Investor's Business Daily on MSN
Eli Lilly Rises, Again, After EMA Groups Recommends Mounjaro For Children As Young As 10
On Friday, an EMA committee recommended extending the use of Eli Lilly's type 2 diabetes drug, Mounjaro, to children as young ...
Eli Lilly will cut the price of its most commonly prescribed insulin products by 70% and expand a program that caps patient costs at $35 per month, the company said on Wednesday. "While the current ...
Dec 12 (Reuters) - The European Medicines Agency's committee on Friday recommended extending the use of Eli Lilly's ...
Eli Lilly's popular drug Mounjaro will be added to China's state-run health insurance scheme from January 1 for patients with ...
Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...
Why Eli Lilly Stock Keeps Pushing Higher Eli Lilly (LLY) has been grinding higher again, with shares up roughly 2% over the ...
Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...
Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...
A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback